Showing 1136 results
-
Press release /Filing acceptance marks second Priority Review granted to Kymriah by the FDA for two distinct indications, underscoring the potential of first ever FDA-approved CAR-T therapy EMA granted…
-
Press release /Kisqali is the CDK4/6 inhibitor with the largest body of first-line evidence demonstrating consistent, superior and sustained efficacy vs. endocrine therapy alone[1] CHMP opinion is…
-
Press release /Pre-specified analysis provides insight into maintenance treatment effectiveness with like-for-like comparison of brolucizumab versus aflibercept over entire week 36 to 48 treatment period …
-
Press release /Real-world evidence confirms Cosentyx® efficacy and safety consistent with previously reported clinical studies[1]-[4] Novartis presents a large program of real-world evidence at the 27th…
-
Press release /Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures of disease activity vs. interferon beta-1a MS severely affects…
-
Press release /Tasigna is the first and only second-generation tyrosine kinase inhibitor approved in the EU for the treatment of Ph+ CML-CP in children Approval builds on a series of Tasigna regulatory…
-
Press release /Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart Association…
-
Press release /Inclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk…
-
Press release /Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versus mometasone furoate1 QMF149 showed improvement in peak…
-
Press release /Approval based on results from pivotal Phase III ASCEMBL trial, in which Scemblix® (asciminib) nearly doubled the major molecular response rate vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) with a more…